January 13, 2017
SBI Biotech said on January 10 that it will grant an exclusive license for its investigational autoimmune disease treatment SBI-9674 to Kyowa Hakko Kirin. Under the deal, Kyowa Kirin will obtain exclusive worldwide rights to develop, manufacture, and commercialize the...read more